Faculty & Staff Detail
Melinda E. Lull, Ph.D.
Title: Assistant Professor
Office: WEGPHR 310
Phone: (585) 899-3730
Education: Post-Doctoral Fellowship, Virginia Commonwealth University
Ph.D., Penn State College of Medicine
B.A., St. John Fisher College
Dr. Lull is a 2004 graduate of St. John Fisher College, where she received a B.A. in anthropology, with minors in both biology and chemistry. Dr. Lull went on to earn her Ph.D. in Pharmacology from Penn State University College of Medicine in 2009. Following postdoctoral studies at Virginia Commonwealth University, Dr. Lull returned to St. John Fisher College in the summer of 2010 to begin her tenure as Assistant Professor in the Department of Pharmaceutical Sciences at the Wegmans School of Pharmacy.
Dr. Lull has pursued many research interests in diverse subject areas, including:
- Identifying protein biomarkers of alcohol abuse in serum. These studies were conducted to help develop diagnostic tests that recognize patterns of alcohol use and abuse in human patients.
- Screening protein markers of tissue damage and repair in the plasma of pediatric patients undergoing cardiopulmonary bypass procedures for the repair of heart defects. This project was conducted via collaboration with the Penn State Children’s Hospital in an effort to better understand pathological processes occurring during bypass, and to learn how to better treat patients during and following this invasive procedure.
- Mapping the protein and gene expression profiles in the brain after cocaine self-administration and periods of abstinence. This project formed the basis of Dr. Lull’s dissertation work at Penn State, aimed at identifying molecular processes that are changed by cocaine and may contribute to the long-term craving and high-rates of relapse associated with cocaine abuse.
Dr. Lull’s current laboratory research focuses on the effects of environmental toxins on the brain. Through understanding of the molecular responses of the brain to these toxins, she seeks to explore the links between environmental exposures and the development of neurological disorders such as Alzheimer’s disease and autism. Beyond the laboratory, Dr. Lull has a strong interest in public health outreach and community service. Dr. Lull has spent time in Guinea, West Africa and with WSOP students in El Salvador where she assisted in pharmacy services and health outreach. She is also involved with a number of local and domestic service organizations.
Lull ME, Piacentino JJ, Traina AN. Stability of U-500 regular insulin in prefilled syringes. J Am Pharm Assoc 2013; 53(3): 304-306. [PMID: 23699679]
Levesque S, Taetzsch T, Lull ME, Johnson J, McGraw C, Block ML. Class A scavenger receptors and the MAC1 receptor have distinct roles in diesel exhaust particle-induced microglial activation and loss of dopaminergic neuron function. J Neurochem 2013; 125(5): 756-765. [PMID: 23470120]
Levesque S, Taetzsch T, Lull ME, Stadler K, Kodavanti U, Johnson J, Kodavanti P, Block ML. Diesel exhaust activates and primes microglia: air pollution and neuroinflammation. Environ Health Perspect 2011; 119: 1149-1155. [PMID: 21561831]
Lull ME, Levesque S, Surace MJ, Block ML. Chronic apocynin treatment attenuates beta-amyloid plaque size and microglia number in hAPP(751)SL mice. PLOS One 2011; 6: e20153. [PMID: 21655287]
Lull ME, Block ML. Microglial activation and chronic neurodegeneration. Neurotherapeutics 2010; 7: 354-365. [PMID: 20880500]
Freeman WM, Lull ME, Patel KM, Bruchlacher RB, Morgan D, Roberts DCS, Vrana KE. Gene expression changes in the mesolimbic pathway following abstinence from cocaine self-administration. BMC Neuroscience 2010; 11: 29-42. [PMID: 20187946]
Lull ME, Freeman WM, VanGuilder HD, Vrana KE. The future of neuroproteomics in drug abuse research. Drug and Alcohol Dependence 2010; 107: 11-22. [PMID: 19926406]
Lull ME, Erwin MS, Morgan D, Roberts DCS, Vrana KE, Freeman WM. Persistent proteomic alterations in mPFC with abstinence from cocaine self-administration. Proteomics: Clinical Applications 2009; 3:462-472. [PMID: 20161123]
Lull ME, Freeman WM, Vrana KE, Mash DC. Functional genomics of human cocaine abuse. Ann NY Acad Sci 2008; 1141:58-75 (Invited Review). [PMID: 18991951]
Lull ME, Carkaci-Salli N, Freeman WM, Myers JL, Midgley F, Thomas NJ, Kimatian SJ, Vrana KE, Undar A. Plasma proteomic biomarkers in pediatric cardiac patients undergoing cardiopulmonary bypass procedures. Pediatric Research 2008; 63(6): 638-644. [PMID: 18317239]
Freeman WM, Patel KM, Bruchlacher RB, Lull ME, Erwin M, Morgan D, Roberts DCS, Vrana KE. Persistent alterations in mesolimbic gene expression with abstinence from cocaine self-administration. Neuropsychopharm 2008; 33(8): 1807-1817. [PMID: 17851536]
Lull ME, Freeman WM, Kimatian SJ, Myers JL, Midgley F, Undar A, Vrana KE. Plasma Proteomics: A Noninvasive Window on Pathology and Pediatric Cardiac Surgery. ASAIO 2006; 52(5): 562-566. [PMID: 16966860]
Freeman WM, Lull ME, Guilford M, Vrana KE. Depletion of abundant proteins from non-human primate serum for biomarker studies. Proteomics 2006; 6(10): 3109-3113. [PMID: 16619306]
Freeman WM, Gooch RS, Lull ME, Worst TJ, Walker SJ, Xu ASL, Green H, Pierre PJ, Grant KA, Vrana KE. ApoAII is an elevated biomarker of chronic non-human primate ethanol self-administration. Alcohol and Alcoholism 2006; 41(3): 300-305. [PMID: 16581821]
Recent Poster Presentations:
Lull ME, Anand S, Birnie C, Chablani L, Connor K, Corigliano A, Dave V, Gandhi M, Nagel A, O’Brocta R, Parkhill A, Sapinoro R, Souza J, Woodruff A, Mathews JL. WSOP prescription for innovation – use as needed (PRN). 2013, American Association of Colleges of Pharmacy Annual Meeting.
Lull ME, Traina AN, Mathews JL. Using classroom technology for pre- and post-lecture reviews. 2013, American Association of Colleges of Pharmacy Annual Meeting.
Lull ME, Souza J, Avery L, Cipriano G, Dave V, Phillips E, Woytowish M, Birnie C. Implementation and evaluation of a strategic professional development program. 2013, American Association of Colleges of Pharmacy Annual Meeting.
Meyer A, Vaughn N, Hall M, Stryker M, Lull ME. Fructose-derived advanced glycation end products (AGEs) enhance neuroinflammation and alter immune function in the brain. Abstract #160. 2013, American Pharmacists Association Annual Meeting.
Kratochwill LN, Overslaugh J, McClary C, Lull ME, Traina AN. Glycemic control in gestational diabetes: insulin detemir versus neutral protamine hagedorn (NPH) insulin. Abstract #316343. 2012, American Society of Health Systems Pharmacy Midyear Clinical Meeting.
Smith K, Utter C, Bodah M, Vaughn N, Lull ME. Dose related cell death and proinflammatory gene expression is seen in microglia treated with high concentrations of fructose. Abstract #316542. 2012, American Society of Health Systems Pharmacy Midyear Clinical Meeting.
Zahorian TM, Hui AC, Lull ME, Lyons-Patterson J, Traina AN. Once weekly exenatide as adjunct management of type 1 diabetes mellitus. Abstract #317260. 2012, American Society of Health Systems Pharmacy Midyear Clinical Meeting.
Utter CR, Bova RJ, Mathews JL, Lull ME. Individualized reflective learning through portfolio use in pharmacy school education. 2012, American Association of Colleges of Pharmacy Annual Meeting.
Hill J, Teijelo C, To H, Meyer A, Micca E, Vaughn N, Lull ME. Environmental toxins linked to neurodegeneration and autism activate the brain’s immune system. Abstract #310. 2012, American Pharmacists Association Annual Meeting.
Jarbe RL, Piette NM, Parkhill AL, Lull ME, Mathews JL. Implementing a substances of abuse outreach program in the Rochester City School District. Abstract #326, 2012 American Pharmacists Association Annual Meeting.
Hui A, Schwier N, Lull ME, Malik R, Lyons-Patterson J, Traina AN. Beyond Insulin: Liraglutide in Type 1 Diabetes Mellitus. 2011, American Society of Health Systems Pharmacy Midyear Clinical Meeting.
Lull ME, Mathews JL, Jannetta EC, Birnie CR. Student-led learning in the pharmaceutical sciences curriculum. 2011, American Association of Colleges of Pharmacy Annual Meeting.